---
schema_version: "secwatch.filing_event.v1"
accession: "0001932393-23-000111"
form_type: "8-K"
ticker: "GEHC"
cik: "0001932393"
company_name: "GE HealthCare Technologies Inc."
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:24:29.981388+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GE HealthCare Q2 revenues up 9% organically; raises FY2023 guidance

## Summary
- Revenue $4.8B, +7% reported, +9% organic; organic orders +6%.
- Net income $418M ($0.91 EPS) vs $485M ($1.04) prior year; adjusted EPS $0.92 vs $1.15.
- Imaging revenue +9% organic to $2.6B; Pharmaceutical Diagnostics +20% organic to $568M.
- FY2023 guidance raised: organic revenue growth 6-8% (prior 5-7%); adjusted EPS $3.70-$3.85 (prior $3.60-$3.75).
- Adjusted EBIT margin guidance 15.0%-15.5%, free cash flow conversion 85%+.

## SEC filing metadata
- accession: 0001932393-23-000111
- form_type: 8-K
- ticker: GEHC
- cik: 0001932393
- company_name: GE HealthCare Technologies Inc.
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1932393/000193239323000111/0001932393-23-000111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1932393/000193239323000111/gehc-20230725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001932393-23-000111
- JSON: https://secwatch.observer/filing/0001932393-23-000111.json
- Plain text: https://secwatch.observer/filing/0001932393-23-000111.txt

## Key facts
- Earnings Releases
  GE HealthCare Technologies Inc. reported second quarter ended June 30, 2023 results: revenue $4.8 billion, net income $418 million, EPS $0.91. Guidance raised.
  - Period: second quarter ended June 30, 2023
  - Revenue: $4.8 billion
  - Net income: $418 million
  - EPS: $0.91
  - Guidance: raised
  - Result: reported results
  source text: raising our top- and bottom-line guidance for the full year as we execute our precision care strategy. ” Second Quarter 2023 Total Company Financial Performance • Revenues of $4.8 billion increased 7% reported and 9% on an Organic basis* year-over-year. Foreign exchange negatively impacted growth by 2%. • Total company orders increased 6% organically, driven by
  evidence_url: https://www.sec.gov/Archives/edgar/data/1932393/000193239323000111/0001932393-23-000111-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.